Tirzepatide (A service available when needed but not included in promotional content.) A dual-receptor therapy targeting GLP-1 and GIP to enhance appetite control, blood sugar balance, and metabolic support
Novo Nordisk is reducing production of Victoza and discontinuing supply in some markets to increase its production capacity for Ozempic
It shows up in sodas, desserts, cereals, sauces, flavored yogurts, and countless packaged foods
Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events [4]
Common side effects of this solution are nausea, vomiting, diarrhea, stomach pain, constipation, and headaches, which usually improve with time
Airway hyperresponsiveness in asthma: measurement and clinical relevance